
Albireo Pharma ALBO
Quarterly report 2022-Q3
added 11-08-2022
Albireo Pharma Cash Conversion Cycle 2011-2025 | ALBO
Annual Cash Conversion Cycle Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.55 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.55 K | -1.55 K | -1.55 K |
Quarterly Cash Conversion Cycle Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -511 | -444 | -2.09 K | - | -1.33 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 251 | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 251 | -2.09 K | -680 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AbbVie
ABBV
|
285 | $ 223.01 | -0.99 % | $ 395 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.68 | 1.85 % | $ 777 M | ||
|
Aclaris Therapeutics
ACRS
|
-881 | $ 3.38 | 3.21 % | $ 261 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-400 | $ 1.33 | -1.48 % | $ 7.25 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
AstraZeneca PLC
AZN
|
-58 | $ 90.34 | -1.28 % | $ 96.9 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
166 | $ 25.76 | 0.19 % | $ 1.25 B | ||
|
Anika Therapeutics
ANIK
|
270 | $ 9.53 | -1.19 % | $ 140 M | ||
|
Aytu BioScience
AYTU
|
174 | $ 2.33 | 2.3 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Axon Enterprise
AXON
|
86.2 | $ 586.28 | 3.15 % | $ 44.4 B | ||
|
Biogen
BIIB
|
387 | $ 173.03 | -2.55 % | $ 25.2 B | ||
|
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | ||
|
Benitec Biopharma
BNTC
|
141 | $ 12.91 | 0.78 % | $ 531 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
209 | $ 11.55 | 8.86 % | $ 747 M | ||
|
Catalyst Biosciences
CBIO
|
391 | $ 15.32 | 5.73 % | $ 1.01 B | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Cerus Corporation
CERS
|
59.2 | $ 2.14 | 13.23 % | $ 395 M | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | ||
|
Bristol-Myers Squibb Company
BMY
|
60.4 | $ 51.05 | -0.32 % | $ 103 B | ||
|
Abeona Therapeutics
ABEO
|
387 | $ 5.5 | 0.46 % | $ 118 M | ||
|
ADiTx Therapeutics
ADTX
|
-4.31 K | $ 2.36 | -7.29 % | $ 31.1 K | ||
|
BioXcel Therapeutics
BTAI
|
-2.28 K | $ 2.1 | -4.34 % | $ 5.32 M | ||
|
Coherus BioSciences
CHRS
|
326 | $ 1.42 | 6.77 % | $ 134 M | ||
|
Celldex Therapeutics
CLDX
|
-6.08 K | $ 28.33 | 0.5 % | $ 1.82 M | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
Baudax Bio
BXRX
|
-14.3 | - | 0.59 % | $ 63 K | ||
|
Завод ДИОД
DIOD
|
-32.7 | - | - | - |